Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michele Palazzo
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
ORCID:
0009-0007-7893-0290
Observed ORCID:
0009-0007-7893-0290
OpenAlex ID:
A5113223738
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022
·
Federica Morano
, Alessandra Raimondi
, et al.
·
Journal of Clinical Oncology
·
146
PDF
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2024
·
Filippo Pietrantonio
, Federica Morano
, et al.
·
Clinical Cancer Research
·
23
PDF
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
2020
·
Filippo Pietrantonio
, Federica Morano
, et al.
·
Clinical Colorectal Cancer
·
17
PDF
Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings
2024
·
Francesca Bianchi
, Valentino Le Noci
, et al.
·
PLoS ONE
·
9
PDF
Updated results and subgroup analysis by presence of liver metastases of a phase I/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC).
2024
·
Filippo Pietrantonio
, Federica Morano
, et al.
·
Journal of Clinical Oncology
·
4
Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).
2024
·
Francesco Iachetta
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
1
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors
2024
·
Filippo Ghelardi
, Giovanni Fucà
, et al.
·
Digestive and Liver Disease
·
1
PDF
Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).
2023
·
Francesco Iachetta
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
1
Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial
2026
·
Silvia Marsoni
, Clara Montagut
, et al.
·
Nature Cancer
PDF
Microbiome alterations in mismatch-repair deficient metastatic colorectal cancer patients
2026
·
Gianmarco Piccinno
, Paolo Manghi
, et al.
·
Scientific Reports
PDF
Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.
2025
·
Filippo Pietrantonio
, Giovanni Randon
, et al.
·
Journal of Clinical Oncology
Figure 2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Figure S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Figure S2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Table S2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Table 3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Methods S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
PDF
Supplementary Figure S5 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Figure S4 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
PDF
Data from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Figure 1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Table 2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Table S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Supplementary Table S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Table 4 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025
·
Filippo Pietrantonio
, Federica Morano
, et al.
Show more works
View as search
Works count:
38
Citation count:
202
H-index:
4
I10-index:
3
Year
Topic
Type